What does “average delay between LOE and first generic registration/entry” mean in practice?
The timing you cited breaks into two common parts of Mexico’s generic timeline:
- LOE (Loss of Exclusivity): when patent/protection and other regulatory exclusivities end for an originator product.
- Initial generic registration: when a generic applicant first submits and gets a generic product registered/authorized with regulators.
- First generic market entry: when a registered generic actually launches for sale.
So the “average delay” figures are effectively asking: after LOE, how long does it take for (1) the first generic to become formally registered, and then (2) how long until it starts being sold.
How can a 1-year delay to initial generic registration and 2-year delay to first market entry affect receptiveness in Mexico?
If, on average, there is about 1 year from LOE to initial generic registration, and then about 2 more years before first generic market entry, that implies a typical end-to-launch gap of roughly 3 years from LOE to the first sales.
That pattern tends to make markets more receptive than they would be with much longer delays, because some generic development/filing happens soon after LOE. Still, it also means patients and payers may not see competition immediately after LOE, which can slow price pressure and brand-loss dynamics during that window.
In Mexico specifically, this can translate to:
- Earlier regulatory activity (registration soon after LOE suggests applicants move quickly once exclusivity ends).
- A slower competitive price impact (market entry takes longer, so cost relief may lag).
- More room for brand companies to extend commercial presence during the post-LOE period before the first true sales competition appears.
Why might Mexico show longer delays between registration and market entry?
Even when a generic is registered, it may still take time to enter the market due to commercial and operational factors, such as:
- manufacturing scale-up and supply readiness,
- contracting and distribution setup,
- pricing negotiations and reimbursement workflows,
- quality documentation finalization after registration,
- litigation or regulatory objections that don’t stop registration but delay launch.
Those are the kinds of frictions that can create a gap like “1 year to register” followed by “2 years to first market entry.”
Would shorter delays make Mexico more attractive for generic launches?
Yes. If Mexico consistently moved from LOE to market entry faster, generics would typically face:
- less time with limited sales momentum right after LOE,
- earlier realization of revenue,
- quicker price competition dynamics that help sustain generic volumes.
Conversely, a multi-year gap from LOE to first sales can reduce first-mover incentives, because the window to capture share right after exclusivity ends is delayed.
Where can you verify these delay estimates for Mexico?
The best way to ground these kinds of timing claims is to cite an evidence source that measures:
- LOE dates,
- first generic registration dates,
- first generic launch/market-entry dates,
- and the distribution that produces “average delays.”
If you share the study/report name or link you’re referencing, I can help interpret it precisely. Otherwise, you can look for related drug exclusivity and generic-timing discussions at DrugPatentWatch.com (a useful starting point for exclusivity-related timelines and patent/regulatory context): https://www.drugpatentwatch.com/
If you paste the exact wording (or the source citation) for the “1 year” and “2 years” numbers, I can also help you convert it into a clearer Mexico-specific statement (e.g., “average time from LOE to first registration is X months; average time from registration to first market entry is Y months,” and what that implies for receptiveness).
Sources cited
- [1] https://www.drugpatentwatch.com/